Rocked by allegations, Novena Global Healthcare board takes over running of firm from Loh cousins
Sinopharm Capital among investors guarding their interests over the company's accounts
Add BT as a preferred source
Anita Gabriel
Singapore
A GROUP of chafed investors in Novena Global Healthcare Group (NGHG) is moving to guard its interests on concerns about the company's accounts. Among these investors: Sinopharm Capital, the private equity arm of Chinese pharmaceutical giant Sinopharm.
On Friday, NGHG's board shot out a statement that it was "deeply concerned" by recent developments, and has set up a special committee to investigate allegations that the audit signatures on the firm's accounts were forged and to "restructure and scrutinise" its affairs.
TRENDING NOW
Singdollar hits 10-month high against ringgit as investors take refuge in traditional safe haven
Apple joins foldable phone race with US$1,999 passport-shaped iPhone Duo
DBS ‘categorically rejects’ S$1.3 billion claim by 1MDB-linked entities under liquidation
Commodity-finance risks back in focus amid Radiant World scrutiny
